At a press conference at SABCS 2014, Dr Cuzick presents data on preventing breast cancer from the International Breast Cancer Intervention Study-I; designed to investigate the long-term risks and benefits of taking tamoxifen to prevent breast cancer in women at high risk for developing the disease.

After a median of 16 years of following women at high risk for breast cancer, the International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers.

The team found that the reduction in breast cancer incidence remains strong and unabated for 20 years. They also found concerns related to endometrial cancer mortality and development of oestrogen receptor [ER]-negative cancers but they are statistically nonsignificant, and could be chance observations.

Watch the interview or read the news story for more.